Potential mechanisms leading to the abnormal lipid profile in patients with rheumatoid arthritis versus healthy volunteers and reversal by tofacitinib.
about
Is the risk of cardiovascular disease altered with anti-inflammatory therapies? Insights from rheumatoid arthritisType I/II cytokines, JAKs, and new strategies for treating autoimmune diseasesLong-term safety of tofacitinib for the treatment of rheumatoid arthritis up to 8.5 years: integrated analysis of data from the global clinical trials.Deciphering the Potential Pharmaceutical Mechanism of Chinese Traditional Medicine (Gui-Zhi-Shao-Yao-Zhi-Mu) on Rheumatoid ArthritisTofacitinib, an oral Janus kinase inhibitor: analysis of malignancies across the rheumatoid arthritis clinical development programmeComparison of lipid and lipid-associated cardiovascular risk marker changes after treatment with tocilizumab or adalimumab in patients with rheumatoid arthritis.Tofacitinib Ameliorates Murine Lupus and Its Associated Vascular Dysfunction.Does a lack of physical activity explain the rheumatoid arthritis lipid profile?Cardiovascular comorbidity in rheumatic diseases.High-density lipoprotein function in rheumatoid arthritis.JAK-STAT Signaling as a Target for Inflammatory and Autoimmune Diseases: Current and Future Prospects.JAK inhibition in inflammatory bowel disease.The Future of Janus Kinase Inhibitors in Inflammatory Bowel Disease.Rheumatoid Arthritis Pharmacotherapies: Do They Have Anti-Atherosclerotic Activity?Benefit and Risk of Tofacitinib in the Treatment of Rheumatoid Arthritis: A Focus on Herpes Zoster.Tofacitinib for the treatment of psoriasis.Small molecules to the rescue: Inhibition of cytokine signaling in immune-mediated diseases.Antioxidative activity of high-density lipoprotein (HDL): Mechanistic insights into potential clinical benefit.Herpes Zoster and Tofacitinib: Clinical Outcomes and the Risk of Concomitant Therapy.Improvement of High-Density Lipoprotein Function in Patients With Early Rheumatoid Arthritis Treated With Methotrexate Monotherapy or Combination Therapies in a Randomized Controlled Trial.Lymphoma in the Tofacitinib Rheumatoid Arthritis Clinical Development Program.Decernotinib: A Next-Generation Jakinib.Tofacitinib improves atherosclerosis despite up-regulating serum cholesterol in patients with active rheumatoid arthritis: a cohort study.Further evidence that high-density lipoprotein is a chameleon-like lipoprotein.Effects of Baricitinib on Lipid, Apolipoprotein, and Lipoprotein Particle Profiles in a Phase IIb Study of Patients With Active Rheumatoid Arthritis.High Expression of STAT3 in Subcutaneous Adipose Tissue Associates with Cardiovascular Risk in Women with Rheumatoid Arthritis.JAK inhibition as a therapeutic strategy for immune and inflammatory diseases.Tofacitinib restores the inhibition of reverse cholesterol transport induced by inflammation: understanding the lipid paradox associated with rheumatoid arthritis.JAK inhibition as a therapeutic strategy for immune and inflammatory diseases.Lipids in RA: Is Less Not Necessarily More?Lipid profile and effect of statin treatment in pooled phase II and phase III baricitinib studies.The Impact of Biologics and Tofacitinib on Cardiovascular Risk Factors and Outcomes in Patients with Rheumatic Disease: A Systematic Literature Review.Chemical JAK inhibitors for the treatment of rheumatoid arthritis.Immunopathogenesis of Rheumatoid Arthritis.Association between inflammation and systolic blood pressure in RA compared to patients without RA.
P2860
Q26746659-D95D85AD-399C-4355-B834-12BE8D7B6BBAQ26775111-8E132002-A623-4063-BC57-C5D4A26ADF97Q31158500-AF61F00B-4339-4940-8282-40D583CAD43CQ36645778-76BC1D55-1D14-4EAC-9481-F2F8AF8D25C6Q36859619-3FC27713-9C6C-4378-8261-7C8E0C635327Q37282484-069A60A7-44A3-417C-AE75-FD8120CD0476Q37541469-019BF341-B6E3-4114-99E7-7B87361DC708Q37637193-B47A914D-0838-4769-9450-B13F8F0FD41AQ38568465-B84A816D-A4F9-4C97-AA0F-672220292CABQ38680931-B0DE3861-C90A-442E-9742-0FF249A2BF3CQ38751230-C167DC67-419F-4200-8D73-BE2855A3D665Q38761142-8D0601D8-0D02-48EA-922D-A7C982A7B245Q38761961-8C5F2217-AB75-4280-AD58-222F027ED9AAQ38794852-82C56A84-720C-420D-8452-C7DA590F621CQ38837769-F5031F4F-91FE-4520-BB8C-5CAA8FC77CE7Q38856883-23344D98-789D-4053-BF1B-EE369F68E392Q39413866-B9D3185E-536B-412C-BED8-F712C4D29F6DQ41115717-A1FE3740-2744-461D-A73A-30360BCB4C7EQ41912068-2C44C0FA-2AB1-43D8-BE0E-4C7C650B9B38Q41914520-CE711F76-13E7-4DCC-9040-3551FD1D5FC7Q41931494-EF5DF6FF-CA86-495E-B14D-6541EA709256Q42394345-46BD10E2-7686-4EDE-A68A-42F13682677EQ42696887-A3177579-57C2-483D-A291-48D3C0E76EEEQ42874127-15F9910D-6B4C-43B4-82FD-032F62788FCBQ44067316-807E7986-EAE3-47C2-BE9B-0D34155852EFQ47408388-B90B2ADC-53D4-4F08-83F2-3D5590B44FF8Q47439880-651D02CE-7C48-4694-A54E-946B862170A2Q48227295-40D0DF09-0F99-456B-B329-8144B531E786Q48556502-81594EA4-6EE9-4C3E-88C4-B514461CCF99Q49721726-3FD62FAA-ABA5-4D87-BCDA-89E9D8DCD770Q49792187-31BDCDC2-11A3-45CC-8271-C7BE8C9FCA6AQ50109832-ED8ECC43-C4C2-4ED7-AF19-C82B87C59AADQ54172510-96C2F22F-D128-4040-B95D-1D155603B86AQ54430437-9EE1EF7C-F74C-45DC-A474-6C8D72E43AB7Q55043697-CC36EC56-85A5-48D3-A440-BE568037B57D
P2860
Potential mechanisms leading to the abnormal lipid profile in patients with rheumatoid arthritis versus healthy volunteers and reversal by tofacitinib.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on March 2015
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Potential mechanisms leading t ...... s and reversal by tofacitinib.
@en
Potential mechanisms leading t ...... s and reversal by tofacitinib.
@nl
type
label
Potential mechanisms leading t ...... s and reversal by tofacitinib.
@en
Potential mechanisms leading t ...... s and reversal by tofacitinib.
@nl
prefLabel
Potential mechanisms leading t ...... s and reversal by tofacitinib.
@en
Potential mechanisms leading t ...... s and reversal by tofacitinib.
@nl
P2093
P2860
P356
P1476
Potential mechanisms leading t ...... s and reversal by tofacitinib.
@en
P2093
Andrea Zuckerman
Carine Beysen
Christina Charles-Schoeman
Howard Schwartz
Irina V Kaplan
Jean Davignon
Marc K Hellerstein
Mark Milad
Richard Riese
Roy Fleischmann
P2860
P304
P356
10.1002/ART.38974
P577
2015-03-01T00:00:00Z